Abstract
The management of sepsis has been a challenging and perplexing field for clinicians, investigators, and basic scientists. The persistently high mortality over the several decades that antibiotics have been available suggests that an additional approach can no longer emphasize only antimicrobial and supportive therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Centers for Disease Control (1990) Increase in national hospital discharge survey rates for septicemia-United States, 1979–1987. JAMA 263: 937–938
Bryant RE, Hood AF, Hood CE (1971) Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 127: 120
Bayston K, Tomlinson M, Cohen J (1990) In vitro induction of tumor necrosis factor alpha ( TNF-a) by cell free supernatants from clinical isolates of gram-positive bacteria. ICAAC (Abst) p 136
Tracey KJ, Beutler B (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–473
Waage A, Espevik T (1987) Association between tumor necrosis factor in serum and fatal out- come in patients with meningococcal disease. Lancet 319: 355–357
Girardin E, Grau GE, Dayer JM, et al. (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319: 397–400
Debets JM, Kampmeijer R, van der Linden MP, et al. (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489–4194
Damas P, Reuter A, Gysen P, et al. (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975–978
Knoll S, Manzor O, Dunn M, et al. (1992) Serum and cell associated cytokines in patients with the septic Syndrome. ICAAC (Abst) p 372
Marks JD, Marks CB, Luce JM, et al. (1990) Plasma tumor necrosis factor in patients with septic shock: Mortality rate, incidence of adult respiratory distress Syndrome. Am Rev Respir Dis 141: 94–97
Bauss F, Droge W, Mannel DN (1987) Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun 55: 1622–1625
Michie HR, Spriggs DR, Manogue KR, et al. (1988) Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104: 280–286
Warren RS, Starnes F, Fabrilove JL, Oettgen HF, Brennan MF (1987) The acute metabolic effects of tumor necrosis factor in humans. Arch Surg 122: 1395–1400
Tracey KJ, Beutler B, Lowry SF, et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474
Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 232: 977–980
Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–871
Opal SM, Cross AS, Kelley NM, et al. (1990) Efficacy of a monoclonal antibody directed against TNF in protecting neutropenic rats from lethal infection with P. aeruginosa. J Infect Dis 161: 1148–1152
Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal an–tibody to TNF-alpha in experimental gram-negative shock. J Infect Dis 162: 421–427
Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662–664
Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KR, Kenney JS (1989) Antibodies to cachectin/TNF reduce interleukin-1 beta and interleukin–6 appearance during lethal bacteremia. J Exp Med 170: 1627–1633
Hinshaw LB, Tekamp-Olson P, Chang ACK, et al. (1990) Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor ( TNF-alpha ). Circ Shock 30: 279–292
Jesmok GJ, Lindsey DC, Fournel MA, et al. (1991) Possible mechanism of protection afforded by tumor necrosis factor monoclonal antibody in E. coli challenged pigs. ICAAC (Abst) p 112
Ladehoff DK, Collins MS, Mehton NS (1991) Lethal administration of monoclonal antibody to tumor necrosis factor is protective in experimental Klebsiella pneumoniae pneumonia. ICAAC (Abst) p 189
Hector RF, Collins MS, Ladenhoff-Guiles D (1992) Use of murine anti-TNF monoclonal promotes survival in a swine model of Escherichia coli meningitis. ICAAC (Abst) p 270
Wayte J, Silva A, Cohen J (1991) Role of tumor necrosis factor ( TNF) in experimental gram-positive sepsis. ICAAC (Abst) p 230
Zanetti G, Kohler J, Neumann D, et al. (1991) Failure of anti-TNF MAb in preventing death in Peritonitis induced gram-negative bacteremia in mice. ICAAC (Abst 790) p: 230
Exley AR, Cohern J, Buurman W, et al. (1990) Monoclonal antibody to TNF in severe septic shock. Lancet 335: 1275–1276
Saravolatz LD, Spooner C, Markowitz N, et al. (1991) Safety and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor. Seventeenth International Congress on Chemotherapy (Abst 865 )
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Saravolatz, L.D., Pokriefka, R.A., Markowitz, N. (1993). Monoclonal Antibody against TNF: A Non-Antibiotic Strategy for the Treatment of Sepsis. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1993. Yearbook of Intensive Care and Emergency Medicine 1993, vol 1993. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84904-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-84904-6_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56463-8
Online ISBN: 978-3-642-84904-6
eBook Packages: Springer Book Archive